Reference49 articles.
1. ACMG Work Group on Management of Pompe Disease, Kishnani, P. S., Steiner, R. D., Bali, D., et al. (2006). Pompe disease diagnosis and management guideline. Genetics in Medicine, 8, 267–288.
2. Amalfitano, A., McVie-Wylie, A. J., Hu, H., et al. (1999). Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proceedings of the National Academy of Sciences of the United States of America, 96, 8861–8866.
3. Amalfitano, A., Bengur, A. R., Morse, R. P., et al. (2001). Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial. Genetics in Medicine, 3, 132–138.
4. American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). (2009). Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle & Nerve, 40, 149–160.
5. Ausems, M. G., Kroos, M. A., Van der Kraan, M., et al. (1996). Homozygous deletion of exon 18 leads to degradation of the lysosomal alpha-glucosidase precursor and to the infantile form of glycogen storage disease type II. Clinical Genetics, 49, 325–328.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献